VivoSeq
Gastroenterology

Gastroesophageal Reflux Disease

73

Pipeline Programs↗

16

Active Trials↗

37

Companies Involved↗

Gastroesophageal Reflux Disease is a moderately active landscape with 73 programs across 37 companies. The most active players are Otsuka, Novartis, Onconic Therapeutics Inc.. 22 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

25/100

Mech. Concentration

29/100

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

2 programs

Phase 1Novartis logo

Novartis

1 program

Phase 2O

Onconic Therapeutics Inc.

1 program

Phase 2E

Edusa Pharmaceuticals, Inc.

1 program

Phase 2K

Kenvue Brands

1 program

Phase 2Eisai logo

Eisai

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

99%

Small molecule

80 of 81 classified programs — the dominant modality here.

1%ALL OTHERSProtein / enzyme11%

Small molecule leads; the ring shows all 81 classified programs, each share of the total. Modality classified for 100% of 81 pipeline programs.

Analysis

Trial Status

117

clinical trials

Completed89 · 76%
Not yet recruiting9 · 8%
Unknown status8 · 7%
Recruiting7 · 6%
Withdrawn2 · 2%
Terminated2 · 2%

Clinical Trials

Trial Activity

117 trials

Treatment of Gastroesophageal Reflux Disease in Infants
Recruiting·OOdense University Hospital·Phase 4·NCT06255886·96 enrolled
Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole
Recruiting·CCarnot Laboratories·Phase 4·NCT06991348·128 enrolled
Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease
Recruiting·TTanta University·Phase 4·NCT06564246·44 enrolled
Effect of Baclofen in Management of Patients With Gastroesophageal Reflux Disease Symptoms
Recruiting·—·Phase 2/3·NCT07063576·60 enrolled
Heartburn, Gastroesophageal Reflux Disease
Recruiting·IIncheon St.Mary's Hospital·Phase 4·NCT07268820·160 enrolled
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Recruiting·Takeda logoTakeda·Phase 2·NCT02616302·70 enrolled
Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
Recruiting·—·N/A·NCT06984484·208 enrolled
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease
Not yet recruiting·OOnconic Therapeutics Inc.·Phase 3·NCT07160790·321 enrolled
Stellate Ganglion Block on Gastroesophageal Reflux Disease
Not yet recruiting·—·N/A·NCT06319521·80 enrolled
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Not yet recruiting·CCinclus Pharma Holding AB·Phase 3·NCT07037875·500 enrolled
The Effect of Probiotic and Zinc Supplementation in Patients With Gastroesophageal Reflux Disease
Not yet recruiting·—·Phase 4·NCT06664008·120 enrolled
Impact of Glossopharyngeal Nerve Block on Swallowing Difficulties Caused by Gastroesophageal Reflux Disease
Not yet recruiting·—·N/A·NCT06328205·80 enrolled
Effect of Lidocaine Block on Gastroesophageal Reflux Disease
Not yet recruiting·MMuhammad·N/A·NCT06304142·80 enrolled
Impact of Blocking the Glossopharyngeal Nerve on Gastroesophageal Reflux Disease
Not yet recruiting·MMuhammad·N/A·NCT06304870·80 enrolled
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Not yet recruiting·CCinclus Pharma Holding AB·Phase 3·NCT07313774·1,050 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)